Aurinia Pharmaceuticals Inc. (AUPH) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-11

Key Insights

Aurinia Pharmaceuticals successfully completed its acquisition of Kezar Life Sciences on May 8-11, 2026, with 80.24% of outstanding shares tendered at $6.955 per share in cash plus one CVR per share, exceeding the minimum tender condition.
The acquisition was completed under Delaware Section 251(h) merger provisions, eliminating the need for stockholder vote and enabling swift integration of Kezar as a wholly owned subsidiary of Aurinia.
All Kezar employee stock options became fully vested upon merger completion, with in-the-money options converted to cash payouts plus CVRs and out-of-the-money options cancelled with no consideration paid.
The contingent value rights agreement dated May 11, 2026 creates potential future payment obligations to shareholders based on undisclosed milestone conditions, adding financial risk beyond the fixed $6.955 cash component.

Want the newest filings?

This analysis covers the filing from 2026-05-11. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-23

Aurinia has appointed a new CEO, Kevin Tang, who is the Chair of the Board and has extensive experience in the life sciences industry.
The company has also appointed a new COO, Ryan Cole, and a new CFO, Michael Hearne, who both have relevant experience in their roles.
The previous CEO, President, COO, CMO, and CFO have all departed the company, which suggests a significant leadership change.

Filed: 2026-02-26

Aurinia Pharmaceuticals reported its financial results for the three and twelve months ended December 31, 2025, providing an update on its recent business progress.
The company's financial performance and key operational updates are disclosed in the press release, which is attached as an exhibit to the 8-K filing.
Investors should review the financial results and progress updates to assess the company's performance and future prospects.

Other reports for Aurinia Pharmaceuticals Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.